BlossomHill Therapeutics Reports Q2 Data, Completes IPO, and Gains FDA Fast Track Designation
BlossomHill Therapeutics reported second quarter 2026 financial results highlighting advances in its oncology pipeline, including full compensation of an upsized $168.3 million IPO and FDA Fast Track designation for BH-30643 regarding NSCLC.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed